Investment in the pharmaceutical manufacturing industry increased by 28%. What instructions does it bring to this year's development?

[ Market analysis of chemical machinery equipment network ] The pharmaceutical manufacturing industry is an important part of China's national economy, and it plays a decisive role in the entire consumer market.
In recent years, my country's pharmaceutical manufacturing industry has also achieved rapid development.
According to data, from 2007 to 2017, the compound growth rate of the main business income of enterprises above designated size in my country's pharmaceutical manufacturing industry reached 16.
8%, from 596.
7 billion yuan to 2,820 billion yuan.
According to data from the 2020 China Economic Annual Report released by the state on January 18, the added value of industries above designated size in the pharmaceutical manufacturing industry will increase by 5.
9% year-on-year; investment in the pharmaceutical manufacturing industry will increase by 28.
4% year-on-year.

 

my country's pharmaceutical industry has entered a stage of rapid development.
Then, in the face of future market development, what development trend does the pharmaceutical industry face? According to the industry, under the influence of the new drug price mechanism centered on “quantity procurement”, the original pharmaceutical industry’s high-pricing, high-cost, and high-margin marketing model has gradually come to an end.
In the future, it will enter high-quality generic drugs and clinically valuable products.
A new development model based on innovative drugs.

 

Volume procurement has also accelerated the integration of the domestic generic drug industry.
Good generic drugs are expected to quickly expand their market share by winning bids through volume procurement, while generic drugs that have not passed the consistency evaluation will be cleared faster, and the market concentration of generic drugs is expected to increase rapidly.
Under the trend of centralized procurement, ordinary generic drugs have entered an era of meager profit.
Prompted by policies such as accelerated approval and medical insurance docking, innovative drugs, first generic drugs, and difficult-to-generic drugs will become the focus of pharmaceutical companies to seek breakthroughs and survive.
Therefore, in the face of future development, pharmaceutical companies need to accelerate the progress of improving the quality of generic drugs and encourage the research and development of new drugs with clinical value.

 

It is understood that in recent years, my country has continued to improve the pharmaceutical innovation environment, and a series of regulatory policies to encourage drug innovation have been implemented.
For example, the path for innovative drugs to be included in the medical insurance catalogue has been gradually expanded, various national funds and a large amount of social capital have been invested in the field of pharmaceutical innovation, and corporate innovation Motivation continues to increase, and R&D investment is gradually increasing.

 

The research and development of innovative drugs has become the main theme of the current industry development.
More and more pharmaceutical companies are also beginning to focus more on new drug innovation.
For example, Sheng Nuoji said that it focuses on the research and development of innovative drugs, and has complete capabilities from drug target discovery and research to clinical drug candidate development and promoting clinical trials of drugs.
It is reported that from 2017 to 2019 (reporting period), Sheng Nuoji's research and development expenses were 45,816,800 yuan, 76,498,900 yuan, and 123,386,400 yuan respectively, maintaining a relatively high level overall.
The company stated that these expenses are mainly due to the company maintaining multiple R&D pipelines to advance the payment of the corresponding clinical trial costs on schedule, and retaining the share payment included in the R&D expenses of the high-level R&D team.
Hengrui Pharmaceuticals is a domestic innovative drug with a rich pipeline of innovative drugs, and blockbuster products are successively approved for listing.
The future growth space is large.
The industry predicts that the company's net profit attributable to its parent will grow at a compound growth rate of more than 20% from 2020 to 2022.

 

　　Intensive promotion of medical policies, the core trend of medical insurance control fees remains unchanged, and the trend of innovation is overwhelming.
According to industry insiders, the next ten years will be an outbreak of original innovative drugs, and innovative drugs will usher in unlimited structural opportunities.
In this process, choosing drugs with differentiated or price advantages for innovative research and development will become very important for pharmaceutical companies and will also become their main research and development trend.

 

　　It is understood that in order to better promote the development of innovative drugs, the approval speed of domestic innovative drugs is constantly accelerating.
As data shows, in 2020, the number of new domestic drugs approved will reach 11, including 6 new tumor drugs, 2 new anesthesia drugs, and 3 new hepatitis C drugs.
At the same time, more than 20 domestically-made innovative drugs have submitted marketing applications in 2020, and the number of domestically-made new drugs approved in 2021 is expected to continue to break through the double digits.
Therefore, in order to seize the industry development vane, pharmaceutical innovation and development are indispensable.

 

　　Original title: 2020 pharmaceutical manufacturing investment growth of 28%, what instructions will this year's industry development bring?